The NK cell subset in CLL patients shows reduced ability to attack cancer cells partly owing to diminished expression of the activating NK receptor NKp30 on the cell surface (Costello et al., 2012). The gene discussed is NCR3; the disease is B-cell chronic lymphocytic leukemia.